Polymer-free drug-coated coronary stents are cost-effective in patients at high bleeding risk: economic evaluation of the LEADERS FREE trial
EuroIntervention 2018;13:1688-1695 published online September 2017. DOI: 10.4244/EIJ-D-17-00286
Antoine Filipovic-Pierucci1*, MD, MPH; Isabelle Durand-Zaleski1,2,3, MD, PhD; Thibault Butel1, MD, MPH; Samantha Greene4, BA; Thomas Hovasse5, MD; Andres Iñiguez6, MD, PhD, FESC; Marco Stefano Nazzaro7, MD, PhD; Keith G. Oldroyd8, MBChB, MD; Suneel Talwar9, MBBS, MRCP, MD; Gert Richardt10, MD; Ute Windhovel11, PhD; Philip Urban12, MD; Marie-Claude Morice5, MD; for the LEADERS FREE investigators
1. Assistance Publique Hopitaux de Paris, URC Eco & Santé Publique, Hôpital Henri Mondor, Créteil, France; 2. Université Paris Est Créteil, Créteil, France; 3. INSERM ECEVE UMR 1123, Paris, France; 4. Biosensors, Morges, Switzerland; 5. Hôpital Privé
Aims: In patients at high risk of bleeding who undergo PCI, the Biolimus A9 polymer-free drug-coated stent (DCS) has superior efficacy and safety compared to a bare metal stent (BMS). We